Thiocolchicoside - CAS 602-41-5
Catalog number: B0084-464811
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C27H33NO10S
Molecular Weight:
563.618
COA:
Inquire
Targets:
GABA Receptor
Description:
Thiocolchicoside is a semi-synthetic derivative of colchicine, an anti-inflammatory glycoside extracted from the flower seeds of superba gloriosa. Thiocolchicoside acts as a GABAA receptor antagonist exhibiting anti-inflammatory and analgesic activity. It is used as a muscle relaxant.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-464811 500 mg $199 In stock
B0084-464811 1 g $299 In stock
Bulk Inquiry
Brife Description:
GABAA receptor antagonist
Purity:
>98%
Appearance:
Yellow Solid
Synonyms:
N-[(7S)-3-(β-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]acetamide; (S)-N-[3-(β-D-Glucopyranosyloxy)-5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]acetamide; Coltramyl; Coltrax; Miorel; Miotens; Muscoril
Storage:
Store at -20°C
MSDS:
Inquire
Melting Point:
>197°C (dec.)
InChIKey:
LEQAKWQJCITZNK-AXHKHJLKSA-N
InChI:
InChI=1S/C27H33NO10S/c1-12(30)28-16-7-5-13-9-18(37-27-24(34)23(33)22(32)19(11-29)38-27)25(35-2)26(36-3)21(13)14-6-8-20(39-4)17(31)10-15(14)16/h6,8-10,16,19,22-24,27,29,32-34H,5,7,11H2,1-4H3,(H,28,30)/t16-,19+,22+,23-,24+,27+/m0/s1
Canonical SMILES:
CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)OC4C(C(C(C(O4)CO)O)O)O
1.Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Pageot C;Bezin J;Smith A;Arnaud M;Salvo F;Haramburu F;Bégaud B;Pariente A;French Network of Pharmacovigilance Centres Drug Saf. 2017 Nov;40(11):1099-1107. doi: 10.1007/s40264-017-0561-y.
INTRODUCTION: ;The consequences of the withdrawal of marketing authorisation of drugs have mostly been studied considering drug prescription patterns for the therapeutic alternatives of the withdrawn drugs. The potential concomitant changes in the reporting of adverse reactions concerning these alternatives have been studied less often.;OBJECTIVE: ;The objective of this study was to analyse the changes in the reporting of adverse events (AEs) for therapeutic alternatives after the withdrawal of three medicines (dextropropoxyphene, pioglitazone and tetrazepam) from the market for safety reasons.;METHODS: ;This study was performed using both the French pharmacovigilance database and the Echantillon Généraliste des Bénéficiaires (a random sample of French health insurance affiliates). For dextropropoxyphene, pioglitazone and tetrazepam alternatives, the number and types of case reports were studied for both the year preceding the first official safety warning and the year following the withdrawal. Reporting rates expressed per 10,000 reimbursements (RR;Reimb;) and per 10,000 treated patients (RR;Pat;) were also compared for the two periods.;RESULTS: ;After dextropropoxyphene withdrawal, case reports and reimbursements increased for tramadol (case reports: +23%, reimbursements: +13%) and codeine (case reports: +74%, reimbursements: +47%), RR;Pat; being significantly increased for tramadol (0.
2.Safety of subcutaneous microinjections (mesotherapy) in musicians.
Navarte DA;Rosset-Llobet J Med Probl Perform Art. 2011 Jun;26(2):79-83.
OBJECTIVE: ;Determine the safety and tolerance of mesotherapy as a technique for the treatment of musculoskeletal complaints in musicians.;METHOD: ;67 patients (55.2% women) were subjected to a total of 267 mesotherapy sessions. A mesotherapy needle or normal needle was used randomly. The drugs employed were thiocolchicoside and diazepam as muscular relaxants, pentoxifylline or buflomedil as vasodilators, and piroxicam as an anti-inflammatory, as directed. A visual analogue scale was used to quantify the pain produced by the microinjections as well as the degree of immediate and midterm side effects as reported on a standard questionnaire.;RESULTS: ;A mean of 155.5 microinjections were performed per session, of which 45.6% were perceived as painful by the patient with a mean severity of 4.3 out of 10. The pain reduced to 0.5 out of 10 after 24 hours. The most sensitive areas were the levator scapulae and splenius muscles. Systemic symptoms were reported by 5.99% of the musicians after the mesotherapy sessions (muscular weakness 1.5%, rash 1.5%, drowsiness 1.1% and itching 1.1%, being the most frequent). The mean severity of these symptoms was 2.77 out of 10. In all cases the symptoms had completely disappeared after 24 hours.
3.Evaluation of the Effect of Mesotherapy in the Management of Osteoarthritis-Related Pain in a Police Working Dog Using the Canine Brief Pain Inventory.
Alves JC;Santos AM Top Companion Anim Med. 2017 Mar;32(1):41-43. doi: 10.1053/j.tcam.2017.07.002. Epub 2017 Jul 5.
CASE DESCRIPTON: ;A 9-year-old, 33.4kg (73.63Lb) male entire drug detection Labrador Retriever Dog was presented with an history of constant lameness from the right thoracic limb, aggravated with exercise and work.;CLINICAL FIDINGS: ;Clinical examination revealed mild signs of pain on the manipulation of the elbow joint, with reduced range of motion on the end feel of joint flexion and extension and crepitation. Radiographic examination of the right elbow joint revealed severe, chronic osteoarthritis, with osteophyte formation on the humeral epicondyles and articular margin of the distomedial humerus, with a narrowed joint space, and osteophytes on the proximal radius, proximomedial ulna, and anconeal process.;TREATMENT AND OUTCOME: ;A solution comprised of a combination of lidocaine, thiocolchicoside, and piroxicam was prepared and applied around the right elbow joint. The animal was rested for 3 days and normal work load was introduced over a 5-day period. The CPBI was completed by the trainer before treatment (T0), 14 days (T1), 1 (T2), 2 (T3), 3 (T4), 4 (T5), 5 (T6), and 6 (T7) months after treatment. Following the mesotherapy session, pain score results consistently declined until the 3-month evaluation moment.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 66548-69-4 CL 218872

CL 218872
(CAS: 66548-69-4)

CL 218872 has been found to be a benzodiazepine agonist and has been found to exhibit anxiolytic and anticonvulsant activities.

CAS 951654-29-8 2-{3-[5-(2-Hydroxypropan-2-yl)-1H-1,3-benzodiazol-1-yl]phenyl}benzamide

2-{3-[5-(2-Hydroxypropan-2-yl)-1H-1,3-be
(CAS: 951654-29-8)

A GABAA receptor modulator that effects against anxiety.

CAS 57717-80-3 CGP7930

CGP7930
(CAS: 57717-80-3)

CGP7930 is a positive allosteric modulator at the GABAB receptor. It has anxiolytic effects in animal studies, and has a synergistic effect with GABAB agonists ...

CAS 3232-36-8 SCS

SCS
(CAS: 3232-36-8)

SCS is a potent and selective partial inhibitor of β1-containing GABAA receptors (IC50 = 4.5, 5.3 and 7.9 nM at α2β1γ1θ, α2β1γ1 and α2β1γ2s GABAA receptors, res...

CAS 63701-55-3 Arbaclofen Hydrochloride

Arbaclofen Hydrochloride
(CAS: 63701-55-3)

Arbaclofen, the R-enantiomer of baclofen, is a selective gamma-amino butyric acid type B receptor agonist used for autism spectrum disorder and fragile X syndro...

CAS 68547-97-7 Isoguvacine hydrochloride

Isoguvacine hydrochloride
(CAS: 68547-97-7)

Isoguvacine hydrochloride is a selective GABA receptor agonist with anticonvulsant and antiepileptic effect, developed for Neuroscience research.

CAS 111205-55-1 CGS 20625

CGS 20625
(CAS: 111205-55-1)

CGS 20625 is a partial agonist for the benzodiazepine binding site of the GABAA receptor used as an anti-anxiety drug. It acts as a central benzodiazepine recep...

CAS 125-33-7 Primidone

Primidone
(CAS: 125-33-7)

Primidone, a pyrimidinedione derivative, could be used as an anticonvulsant agent especially against epilepsy unspecified.

CAS 71424-95-8 3-Methyl-GABA

3-Methyl-GABA
(CAS: 71424-95-8)

3-Methyl-GABA is an activator of GABA aminotransferase.

CAS 133737-32-3 Pagoclone

Pagoclone
(CAS: 133737-32-3)

Pagoclone, an active (+)-enantiomer of the racemate RP 59037, is a ubtype selective partial agonist at GABAA receptor and used for the treatment of panic and an...

Lorediplon
(CAS: 917393-39-6)

Lorediplon is a hypnotic drug acting as a GABAA receptor modulator, differentially active at the alpha1-subunit. It is a novel nonbenzodiazepine of the pyrazolo...

CAS 130477-52-0 L-655,708

L-655,708
(CAS: 130477-52-0)

L-655,708, an inverse agonist of α5 subunit involved in GABAA receptor, has been found to exhibit cognitive performance improvement in biological studies.

CAS 56776-32-0 Etifoxine Hydrochloride

Etifoxine Hydrochloride
(CAS: 56776-32-0)

Etifoxine Hydrochloride is Potentiator of GABAA receptor with anxiolytic and anticonvulsant activity.

CAS 56189-68-5 CGP 13501

CGP 13501
(CAS: 56189-68-5)

CGP 13501 is a positive allosteric modulator of GABAB receptors, potentiating the effects of GABA at this receptor type.

CAS 53188-20-8 Etomidate Hydrochloride

Etomidate Hydrochloride
(CAS: 53188-20-8)

Etomidate hydrochloride is a GABAA receptor agonist used for the induction of general anaesthesia.

CAS 783331-24-8 MRK 016

MRK 016
(CAS: 783331-24-8)

MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator with EC50 value of 3 nM. It has nootropic properties. MRK-016 can produce rapid...

Basmisanil
(CAS: 1159600-41-5)

This active molecular is a highly selective inverse agonist/negative allosteric modulator GABAAα5 receptors. It was developed by Roche to treat cognitive impair...

CAS 1134-47-0 Baclofen

Baclofen
(CAS: 1134-47-0)

Baclofen, an agonist of GABAB receptor, could be effective as a skeletal muscle relaxant and has been also found to have antispastic effect.

CAS 157013-85-9 U 89843A

U 89843A
(CAS: 157013-85-9)

U 89843A is a positive allosteric modulator of GABAA receptors. U 89843A potentiates GABA-induced Cl- currents in the α1β2γ2, α3β2γ2 and α6β2γ2 GABAA receptors....

CAS 945828-50-2 AA 29504

AA 29504
(CAS: 945828-50-2)

AA 29504 is a positive allosteric modulator of GABAA receptors with anxiolytic activity. It modulates both α4β3δ-containing extrasynaptic receptors and α1β3γ2S-...

Chemical Structure

CAS 602-41-5 Thiocolchicoside

Quick Inquiry

Verification code

Featured Items